Oncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research report report published on Wednesday morning. The firm issued a hold rating on the stock.

Other analysts have also recently issued reports about the stock. Northland Securities reissued a market perform rating and set a $2.00 target price on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Brookline Capital Management reiterated a hold rating on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. HC Wainwright cut their target price on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating on the stock in a report on Monday, August 12th. Finally, Northland Capmk lowered Oncternal Therapeutics from a strong-buy rating to a hold rating in a report on Thursday, September 12th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Hold and a consensus price target of $20.00.

Oncternal Therapeutics Stock Performance

NASDAQ:ONCT opened at $1.25 on Wednesday. Oncternal Therapeutics has a one year low of $1.20 and a one year high of $13.14. The business’s 50-day simple moving average is $3.63 and its 200 day simple moving average is $6.67. The stock has a market cap of $3.70 million, a price-to-earnings ratio of -0.10 and a beta of 1.36.

Oncternal Therapeutics (NASDAQ:ONCT) last released its earnings results on Thursday, August 8th. The company reported ($2.89) EPS for the quarter, beating the consensus estimate of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. The company had revenue of $0.80 million during the quarter, compared to analysts’ expectations of $0.24 million. During the same period in the prior year, the business posted ($3.00) EPS. On average, equities research analysts predict that Oncternal Therapeutics will post -11.43 EPS for the current year.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned 0.94% of Oncternal Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.